Electrophoresis Market

Market Definition

Electrophoresis is used to separate and analyze charged biomolecules such as DNA, RNA, and proteins by applying an electric field to a gel or other medium. The market includes all related systems, reagents, gel documentation devices, and specialized software used to perform and analyze these separations.

This method is primarily used in pharmaceutical and disease research and diagnostics. The market covers major applications and key end users of electrophoresis, which helps understand its adoption on a global and regional scale.

Electrophoresis Market Overview

The global electrophoresis market size was valued at USD 3031.4 million in 2024 and is projected to grow from USD 3179.0 million in 2025 to USD 4530.1 million by 2032, exhibiting a CAGR of 5.10% during the forecast period. 

The rising demand for electrophoresis systems for protein analysis in pharmaceutical research, disease profiling, and drug development is a major factor driving this growth. In terms of innovation, the increasing adoption of precast gels as safer alternatives to ethidium bromide in electrophoresis workflows is also shaping laboratory practices across research and diagnostics.

Major companies operating in the electrophoresis industry are UVItec, iGene Labserve, Edvotek Inc., MAESTROGEN INC., Kaneka Eurogentec S.A., Thistle Scientific Ltd., SID Group, Vilber, Bio-Rad Laboratories, Inc., Clinx Science Instruments Co., Ltd., Hoefer Inc., Azure Biosystems Inc., GeneBio Systems, Inc., Thermo Fisher Scientific Inc., and Sartorius AG.

One of the emerging trends in the market is the use of capillary isoelectric focusing-mass spectrometry (cIEF-MS) for detailed protein analysis. This technique separates proteins by their charge and identifies them using mass spectrometry. 

The method is being used in biopharmaceutical manufacturing for quality control and product characterization. Its ability to deliver precise and reliable results supports its growing adoption in advanced research settings.

• In June 2024, CMP Scientific launched the BioSummit CVA system, a next-generation platform for the charge variant analysis of recombinant protein therapeutics. The system was introduced at the 72nd ASMS Conference on Mass Spectrometry and Allied Topics.

Key Highlights:

1. The electrophoresis market size was valued at USD 3031.4 million in 2024.
2. The market is projected to grow at a CAGR of 5.10% from 2025 to 2032.
3. North America held a market share of 34.09% in 2024, with a valuation of USD 1033.3 million.
4. The electrophoresis systems segment garnered USD 1636.6 million in revenue in 2024.
5. The diagnostic segment is expected to reach USD 1890.2 million by 2032.
6. The academic institutions segment is expected to reach USD 1273.5 million by 2032.
7. Asia Pacific is anticipated to grow at a CAGR of 6.07% during the forecast period.

Market Driver

Rising Demand for Electrophoresis Systems for Protein Analysis

The market is driven by the rising demand for electrophoresis systems used in protein analysis. Protein separation and characterization are essential in drug discovery, biomarker identification, and disease mechanism studies. 

Electrophoresis provides a reliable solution for analyzing protein size, charge, and purity. Research laboratories and pharmaceutical companies use these systems to assess protein expression, monitor purification steps, and validate therapeutic targets. 

As the need for accurate protein profiling increases across biomedical and pharmaceutical research, the adoption of electrophoresis systems continues to expand.

• In January 2024, Agilent Technologies Inc. introduced the ProteoAnalyzer, an automated parallel capillary electrophoresis platform, for analyzing proteins. The system simplifies the analysis of complex protein mixtures and improves efficiency in quality control workflows.

Market Challenge

Limited Adoption Due to High Equipment Costs

A major challenge in the electrophoresis market is the high cost of advanced systems and related imaging equipment. These expenses make it difficult for small laboratories and academic institutions to adopt newer technologies. Budget limitations often lead to the extended use of outdated systems, which affects accuracy and throughput. 

Therefore, manufacturers constantly introduce compact and modular systems that offer core functionality at a lower cost. Some companies are also offering flexible financing options and leasing models to support accessibility. These strategies aim to increase adoption while maintaining performance standards.

Market Trend

Rising Adoption of Precast Gels as Safer Alternatives to Ethidium Bromide

The market is experiencing a shift toward the use of precast gels as a safer and more sensitive alternative to traditional ethidium bromide-based staining. Ethidium bromide has been widely used for visualizing nucleic acids but is classified as a mutagen and requires special handling and disposal procedures. 

On the other hand, precast gels are manufactured with non-toxic fluorescent dyes that offer higher sensitivity and clearer band resolution. 

These ready-to-use gels eliminate the need for manual gel casting and staining, reducing variability and preparation time. This trend reflects the growing preference for standardized, safe, and high-performance solutions in molecular biology workflows.

• In August 2024, Biotium launched its precast agarose gels containing GelRed dye, offering a safer and convenient alternative to ethidium bromide for DNA electrophoresis. These gels eliminate manual preparation steps and provide improved sensitivity and safety.

Electrophoresis Market Report Snapshot

Segmentation	Details
By Component	Electrophoresis Systems, Electrophoresis Reagents, Gel Documentation Systems, Software
By Application	Diagnostic, Research, Quality Control & Process Validation
By End User	Academic Institutions, Hospitals & Diagnostic Centers, Pharmaceutical and Biotechnology Companies, Research Organizations, Others
By Region	North America: U.S., Canada, Mexico
	Europe: France, UK, Spain, Germany, Italy, Russia, Rest of Europe
	Asia-Pacific: China, Japan, India, Australia, ASEAN, South Korea, Rest of Asia-Pacific
	Middle East & Africa: Turkey, U.A.E., Saudi Arabia, South Africa, Rest of Middle East & Africa
	South America: Brazil, Argentina, Rest of South America

Market Segmentation:

• By Component (Electrophoresis Systems, Electrophoresis Reagents, Gel Documentation Systems, and Software): The electrophoresis systems segment earned USD 1098.0 million in 2024, due to the rising demand for advanced separation technologies in genomics and proteomics workflows.
•  By Application (Diagnostic, Research, and Quality Control & Process Validation): The diagnostic segment held 42.17% of the market in 2024, due to the increasing use of electrophoresis in disease detection, particularly in oncology and genetic testing.
•  By End User (Academic Institutions, Hospitals & Diagnostic Centers, Pharmaceutical and Biotechnology Companies, and Research Organizations): The academic institutions segment is projected to reach USD 1273.5 million by 2032, owing to extensive investments in life sciences research and training infrastructure.

Electrophoresis Market Regional Analysis

Based on region, the global market has been classified into North America, Europe, Asia Pacific, the Middle East & Africa, and South America.

North America electrophoresis market share stood at 34.09% in 2024, with a valuation of USD 1033.3 million. The region leads due to the high volume of clinical and genomic research. Pharmaceutical and biotechnology companies in North America use electrophoresis for large-scale molecular studies. 

This is further supported by investments in research and advanced laboratory infrastructure, which drives the adoption of electrophoresis systems and reagents. Research institutions and academic centers in the United States and Canada conduct extensive studies in genomics, proteomics, and personalized medicine. 

This research activity has created steady demand for high-precision electrophoresis technologies in clinical and academic settings across the region.

• In April 2025, Roche announced an investment of USD 50 billion in diagnostics and pharmaceuticals in the U.S. over the next five years. It includes the development of new R&D centers and expanded manufacturing facilities in states like Massachusetts, Indiana, Pennsylvania, and California.

Asia Pacific is poised to grow at a CAGR of 6.07% over the forecast period. The growth is attributed to the rising collaborations on the development of new genetic testing systems. 

Research institutes and diagnostic companies across countries such as China, Japan, and India are increasingly working together to design and implement advanced genetic screening solutions. These initiatives require the integration of electrophoresis technologies for sample preparation and analysis. 

As healthcare infrastructure improves and personalized medicine gains traction, the use of electrophoresis in diagnostics and research is expanding rapidly across the region.

• In February 2024, Hitachi High-Tech Corporation collaborated with Sysmex Corporation for developing new genetic testing systems based on capillary electrophoresis sequencers. The collaboration aims to create efficient and cost-effective genetic testing systems suitable for widespread clinical use, addressing the need for shorter measurement times and lower operational costs in the genetic diagnostics field.

Regulatory Frameworks

• In the U.S., electrophoresis devices used for diagnostic purposes are regulated by the U.S. Food and Drug Administration (FDA) under 21 CFR Part 862, which covers clinical chemistry and clinical toxicology devices.
• In Europe, electrophoresis devices fall under the In Vitro Diagnostic Medical Devices Regulation (IVDR) 2017/746, which mandates conformity assessments and CE marking for market access.
• In Japan, electrophoresis devices intended for clinical use must comply with the Pharmaceuticals and Medical Devices Act (PMDA), which includes pre-market approval and quality system requirements.
• In India, the Central Drugs Standard Control Organization (CDSCO) regulates electrophoresis equipment under the Medical Devices Rules, 2017, when used for diagnostic or clinical applications.

Competitive Landscape

Key players in the electrophoresis market are focusing on developing advanced software platforms for managing and analyzing large sets of RNA and DNA electrophoresis data. These platforms are designed to improve workflow efficiency and ensure the accurate interpretation of complex molecular results. 

Companies are investing in software that enables automated data capture, real-time gel documentation, and integration with laboratory information systems. Focusing on features that support high-throughput analysis, data traceability, and compliance with regulatory standards is necessary. 

Strategic efforts include enhancing user interfaces, increasing compatibility with various hardware systems, and offering cloud-based solutions for remote access and collaboration. These initiatives aim to streamline data management and deliver precise and reproducible results across research and diagnostic applications.

• In April 2025, Genedata collaborated with Genmab to launch Genedata Chromatics. The platform streamlines chromatography workflows and integrates RNA and DNA electrophoresis data to support efficient biotherapeutic assessment. It was developed to address inefficiencies caused by fragmented software systems.

List of Key Companies in Electrophoresis Market:

• UVItec
• iGene Labserve
• Edvotek Inc.
• MAESTROGEN INC.
• Kaneka Eurogentec S.A.
• Thistle Scientific Ltd.
• SID Group
• Vilber
• Bio-Rad Laboratories, Inc.
• Clinx Science Instruments Co., Ltd.
• Hoefer Inc.
• Azure Biosystems Inc.
• GeneBio Systems, Inc.
• Thermo Fisher Scientific Inc.
• Sartorius AG

Recent Developments (Product Launch)

• In January 2025, Biotium launched its EMBER Ultra Gel Kits for RNA and DNA gel electrophoresis. The kits feature a pre-coated agarose and loading dye to enable high-sensitivity nucleic acid detection without post-electrophoresis staining, supporting simplified workflows and downstream compatibility with qPCR and sequencing.